Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

DYNIX DIAGNOSTIX

NPI: 1760930697 · FORT PIERCE, FL 34946 · Clinical Medical Laboratory · NPI assigned 09/20/2016

$103K
Total Medicaid Paid
9,413
Total Claims
8,144
Beneficiaries
35
Codes Billed
2018-08
First Month
2023-05
Last Month

Provider Details

Authorized OfficialALTERMAN, SEAN (CHIEF OPERATING OFFICER)
NPI Enumeration Date09/20/2016

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 900 $0.00
2019 3,352 $14.87
2020 79 $3K
2021 1,615 $36K
2022 2,413 $61K
2023 1,054 $2K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 1,395 1,226 $78K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1,187 1,037 $11K
87811 894 790 $10K
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 1,140 1,078 $2K
80053 218 168 $315.15
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 290 80 $158.64
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 216 186 $93.84
82746 29 25 $14.87
G0471 Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) 430 324 $0.00
85027 117 105 $0.00
84478 41 40 $0.00
84075 126 119 $0.00
83036 182 166 $0.00
85025 324 261 $0.00
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled 316 234 $0.00
84443 217 179 $0.00
82607 72 60 $0.00
82435 144 134 $0.00
84132 155 146 $0.00
82040 130 122 $0.00
82306 51 46 $0.00
80050 12 12 $0.00
84460 121 114 $0.00
82374 155 146 $0.00
82247 121 114 $0.00
80061 171 144 $0.00
82310 196 185 $0.00
82947 182 168 $0.00
83718 42 40 $0.00
84450 121 114 $0.00
82565 156 147 $0.00
84155 120 113 $0.00
84295 156 146 $0.00
82465 42 40 $0.00
84520 144 135 $0.00